Dr. Claudia Bardoni | Chemo-Immunotherapy | Best Research Award

Dr. Claudia Bardoni | Chemo-Immunotherapy | Best Research Award

MD FACS, IEO, Italy

Claudia Bardoni is a thoracic surgeon with extensive experience in thoracic surgery and research. Currently, she works as an Associate Thoracic Surgeon at the European Institute of Oncology (IEO) and is a member of the Nova Talent Network. She has worked in various prestigious institutions, including Università degli Studi di Milano and Cleveland Clinic Abu Dhabi.

Profile

orcid

🎓 Education

Although specific educational details are not provided, her experience suggests a strong foundation in medicine and surgery. She has completed fellowships in thoracic surgery, robotics, and microsurgery.

👨‍🔬 Experience

– Thoracic Surgeon at IEO- Resident Doctor at Università degli Studi di Milano- Clinical Fellow at Cleveland Clinic Abu Dhabi- Surgical Fellow at Klinikum Ernst von Bergmann- Medical Doctor in Covid-19 department

🔍 Research Interest

– Thoracic surgery- Lung transplant- Regenerative medicine- Robotics and microsurgery

🏆Awards and Honors

No specific awards or honors are mentioned, but her membership in the Nova Talent Network, which gathers the top 3% of professionals worldwide, is notable.

📚 Publications

– Evaluation of Methodological Quality of Published Guidelines: Dr. Bardoni co-authored a study evaluating the methodological quality of published guidelines for the surgical treatment of pleural mesothelioma, published in the European Journal of Cancer Prevention in 2023.
– Surgical Management of Superior Sulcus Tumors: She was part of a team that published a 20-year experience of surgical management of superior sulcus tumors at an oncological high-volume referral center in Frontiers in Oncology in 2023.
– Surgical Resection of Pulmonary Metastases: Dr. Bardoni contributed to a multicentric study on surgical resection of pulmonary metastases from melanoma in oligometastatic patients, published in Cancers in 2023.
– Non-Small Cell Lung Cancer: She co-authored a 20-year single-center retrospective study on surgically treated pT2aN0M0 non-small cell lung cancer, published in the Journal of Clinical Medicine in 2023.
– Molecular Biomarkers in Lung Cancer: Dr. Bardoni was involved in a narrative review analyzing molecular biomarkers in resected early-stage non-small cell lung cancer, published in Cancers in 2022.

Some of her other research interests and publications focus on:
– Reducing Postoperative Costs: Dr. Bardoni explored ways to reduce postoperative costs in thoracic surgery, including the use of oral management procedures to prevent complications.
– Body Composition and Complications: She investigated the relationship between CT-derived body composition values and complications after pneumonectomy in lung cancer patients ⁴.

Conclusion

This individual has a strong profile, with prestigious affiliations and editorial roles. While they have a solid foundation in research and clinical practice, more emphasis on publishing research findings, securing funding, and international collaborations would strengthen their application for the Best Researcher Award. With some additional focus on showcasing research achievements, they could demonstrate their suitability for the award.

Prof Dr. Catherine Alix-Panabieres | Biopsie Liquide | Excellence in Research

Prof Dr. Catherine Alix-Panabieres | Biopsie Liquide | Excellence in Research

Prof Dr. Catherine Alix-Panabieres , CHU de Montpellier, France

Prof Dr. Catherine Alix-Panabieres is academic and researcher in the field of renewable energy, holds a PhD in Bio systems Engineering from Kangwon National University, South Korea. His academic journey has been marked by a profound dedication to advancing solar energy technologies, specifically in solar thermal harvesting and its integration into agricultural and architectural applications.

Professional Profiles:

Orcid

Google scholar

Position 🏥

Discipline: OncologyFunction: Professeur des Universités – Praticien Hospitalier (PU-PH); Full ProfessorLaboratory: Director of the Laboratory of Detection of Rare Circulating Human – LCCRH, Department of Pathology and Onco-Biology, University Medical Center of Montpellier – IURC, 641, avenue du Doyen Gaston Giraud, 34093 Montpellier Cedex 5 & CREEC/CANECEV, MIVEGEC (CREES), University of Montpellier, CNRS, IRD, Montpellier, France.Phone: +33 4 11 75 99 31 / +33 6 88 80 06 74 (Mobile)Fax: +33 4 67 33 52 81

Academic Qualifications 🎓

2023: University Diploma in Medical Education and Communication2012: Habilitation (University of Montpellier, France)1995/98: PhD obtained on 25th November 1998 (University Louis Pasteur Strasbourg, France)1994/95: Master 2 in Molecular and Cellular Biology (Prof Jules Hoffmann, Nobel prize – ULP Strasbourg, France)

Professional Career Development 🚀

2023-24: Full Professor at the University of Montpellier2010-23: Maître de Conférences – Praticien Hospitalier (UMC and University of Montpellier)1999-2009: Post-doctorant (2 years) then researcher (9 years) at the UMC of Montpellier2022-2026: Visiting Professor at the University of Hamburg, Germany2021-24: Top 25 best researchers at the CHU of Montpellier2020-24: Work-package leader of the European Liquid Biopsy Society (ELBS)2020-23: Consultant for Menarini as an expert in the liquid biopsy field

Key Achievements and Honors 🏆

2016: Active Member of the European Society of Medical Oncology (ESMO)2013-18: Active Member of Pilot committee of the Pole of Cancer Research ‘SIRIC’ – Colon cancer axis2013: Creation and President of the Association « BIODETECT »2006 & 2002: Patents for innovative cancer detection technologies2021: International Liquid Biopsy Society (ISLB) Award for Lifetime Achievement2022: Prestigious Alexandr Savchuk Award

Key Publications 📚

h-index: 58i10-index: 113Citations: 16,738Notable Publications:”Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer.” Br J Cancer. 2023″Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.” J Clin Oncol. 2023″Liquid Biopsy: From Discovery to Clinical Application.” Cancer Discovery 2021

Teaching Activity 🎓

Experience: Over 15 years of teaching in Oncology at the Faculties of Medicine and Sciences, University of MontpellierInternational Teaching: Bari (Italy), Beirut (Lebanon), Zürich (Switzerland), Aarhus (Denmark)Supervision: 20 theses, 9 Master 2, and 10 Master 1 students since 2016Publications: 14 education book chapters and reviews

Short Biography

Professor Catherine Alix-Panabières earned her PhD in 1998 from the University Louis Pasteur in Strasbourg, France. She has made significant strides in the field of oncology, particularly in the optimization of techniques for detecting and characterizing viable circulating tumor cells (CTCs). Notably, she co-coined the term ‘Liquid Biopsy’ and has received numerous awards for her contributions to cancer research. As the director of the Laboratory of Rare Human Circulating Cells (LCCRH), she continues to advance the field with innovative research and international collaborations.Her notable achievements include patents for cancer detection technologies, recognition from prestigious institutions such as the French Academy of Medicine, and significant contributions to the global understanding and application of liquid biopsy techniques in cancer research. Her work has been widely published and cited, reflecting her impact on the field of oncology.

📖 Publications Top Note :

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Demographic Analysis of Cancer Research Priorities and Treatment Correlations

Aligning Cancer Research Priorities in Europe with Recommendations for Conquering Cancer: A Comprehensive Analysis